Rosuvastatin 20mg + Fenofibrate 160mg Tablet in PCD Pharma Franchise in Delhi

Rosuvastatin 20mg + Fenofibrate 160mg Tablet in Pharmaceutical Manufacturing Company in Indore

Rosuvastatin 20mg + Fenofibrate 160mg Tablet in Cardiac Care Pharma Franchise in Pune

Rosuvastatin 20mg + Fenofibrate 160mg Tablet in Pharma Distributors & Suppliers in Bengaluru

Rosuvastatin 20mg + Fenofibrate 160mg Tablet in Pharma Export Company in Kolkata
Rosuvastatin 20mg + Fenofibrate 160mg Tablet in Pharma Franchise Opportunity in Hyderabad

Home/Products /rosuvastatin-20-mg-fenofibrate-160-mg-tablet

About the Product

Description


Rosumore F 20 Tablet is a powerful lipid-lowering combination that unites Rosuvastatin 20 mg, a high-intensity statin, with Fenofibrate 160 mg, a fibrate-class medication. This fixed-dose combination is designed to address complex dyslipidemias, particularly in patients suffering from both elevated LDL-C (bad cholesterol) and high triglyceride levels. Rosuvastatin works by inhibiting the HMG-CoA reductase enzyme to reduce cholesterol production in the liver, while Fenofibrate activates PPAR-alpha receptors, leading to enhanced lipid metabolism and breakdown of triglyceride-rich particles. This dual mechanism offers comprehensive lipid control—reducing total cholesterol, LDL, triglycerides, and increasing HDL-C (good cholesterol). Rosumore F 20 is ideal for patients with mixed dyslipidemia, metabolic syndrome, or type 2 diabetes who are at high cardiovascular risk and require intensive lipid-lowering therapy. The 20 mg statin component ensures strong statin coverage, making this formulation suitable for patients who are not achieving lipid goals with monotherapy or lower combination strengths.

While generally well tolerated, Rosumore F 20 may cause side effects such as headache, muscle pain, back pain, abdominal discomfort, nausea, flatulence, and elevated liver enzymes. The risk of myopathy or rhabdomyolysis is higher with this high-dose statin-fibrate combination, especially in elderly patients or those with kidney disease. Other possible adverse effects include changes in renal function, pancreatitis, or gallstones. Patients should report any signs of unexplained muscle pain, dark-colored urine, or persistent fatigue. Periodic monitoring of liver function, renal function, and muscle enzymes (CPK) is recommended during long-term use.

Rosumore F 20 Tablet is indicated for the treatment of mixed dyslipidemia and severe hypertriglyceridemia in adults at high risk of cardiovascular events, especially those with coexisting conditions like diabetes mellitus, obesity, or coronary artery disease. It is also used as an adjunct to diet in patients who require intensive lipid profile improvement and are unresponsive to monotherapy.

Rosumore F 20 should be used only under the supervision of a qualified physician. It is contraindicated in patients with active liver disease, severe renal dysfunction, gallbladder disease, or known hypersensitivity to statins or fibrates. This medication is not recommended during pregnancy or breastfeeding. Alcohol intake should be limited to reduce liver stress. Patients should continue to follow a lipid-lowering diet and lifestyle modification plan along with the medication. Regular follow-up and blood tests are essential to ensure safety and therapeutic efficacy.

Store Rosumore F 20 Tablet in a cool, dry place, away from moisture and direct sunlight, at a temperature not exceeding 30°C. Keep out of reach of children. Do not use the medicine past its expiry date.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

1. What are the business opportunities for Rosuvastatin 20 mg + Fenofibrate 160 mg Tablet in the PCD pharma franchise market?

Rosuvastatin 20 mg + Fenofibrate 160 mg Tablet is a lipid-lowering combination therapy used for the management of mixed dyslipidemia, high cholesterol, elevated triglyceride levels, and prevention of cardiovascular complications such as heart attack and stroke. Rosuvastatin helps reduce LDL (bad cholesterol), while Fenofibrate lowers triglycerides and improves lipid metabolism, making this combination a widely prescribed cardiovascular and metabolic care segment product. Its strong demand among cardiologists, physicians, and diabetologists creates excellent opportunities in the PCD pharma franchise market.

2. Why should medical distributors include this product in their range?

Medical distributors and wholesalers can benefit from the consistent demand for advanced lipid-management therapies. This combination is commonly prescribed for patients requiring aggressive cholesterol and triglyceride control, ensuring regular repeat prescriptions, stable monthly sales, and continuous market demand across retail and hospital channels.

3. Does Cafoli Lifecare offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma franchise opportunities in the cardiovascular and lipid-management segment, including Rosuvastatin 20 mg + Fenofibrate 160 mg Tablet. We provide monopoly rights, quality-assured manufacturing, promotional support, and reliable product availability to help franchise partners establish a strong presence in the chronic care market.

4. What benefits do wholesalers get by partnering for this product?

Wholesalers and stockists benefit from strong prescription-driven demand, long-term patient usage, and broad acceptance among cardiac and metabolic care specialists. Since dyslipidemia often requires ongoing treatment and monitoring, this product offers steady product movement, repeat business opportunities, and sustainable profitability in pharmaceutical distribution.

5. How can I become a distributor or franchise partner for Rosuvastatin 20 mg + Fenofibrate 160 mg Tablet?

Medical distributors, stockists, and pharma professionals interested in cardiovascular and lipid-lowering products can contact Cafoli Lifecare to discuss pricing, product availability, monopoly franchise rights, and business opportunities. We provide complete support through marketing materials, dependable supply chains, and territory-based franchise assistance to help partners grow their business successfully.